Trastuzumab-based therapy is a standard, targeted treatment for HER2-positive breast cancer in the adjuvant setting. However, patients do not benefit equally from it and the association between HER2 amplification level and patients' survival remains controversial. A systematic review and meta-analysis was conducted by incorporating all available evidence to evaluate the association between disease free survival (DFS) and HER2 amplification level.Three cohort studies involving 1360 HER2-positive breast cancer patients stratified by HER2 amplification magnitude were eligible for meta-analysis. The combined HRs for DFS were 1.05 (95

作者：Qian-Qian, Xu；Bo, Pan；Chang-Jun, Wang；Yi-Dong, Zhou；Feng, Mao；Yan, Lin；Jing-Hong, Guan；Song-Jie, Shen；Xiao-Hui, Zhang；Ya-Li, Xu；Ying, Zhong；Xue-Jing, Wang；Yan-Na, Zhang；Qiang, Sun

来源：Oncotarget 2016 年